FoundMyFitness · 2022-02-08 · Rhonda Patrick (host), Eran Elinav
Dr. Eran Elinav on Microbiome Insights into Personalized Response to Diet, Obesity, and Leaky Gut
59 research-tied claims examined: 6 overstated 2 context 47 supported 4 unverified
6 Overstated
Indigenous hunter-gatherer populations can have a gut microbiome diversity that is tenfold higher than that of individuals living in modern industrialized societies.
"if you look at indigenous populations of humans, uh, hunter-gatherers and so on and so forth, you would find, um, in some studies that the diversity of the microbiome can be tenfold higher than the average diversity that we, um, can see and measure, um, in in the same human beings when they live in modern, quote-unquote, societies or industrialized societies." (said at 0:18:45)
Observational metagenomic studies comparing traditional hunter-gatherer and isolated indigenous populations (such as the Hadza of Tanzania and uncontacted Yanomami Amerindians) to urban industrialized cohorts show that indigenous populations harbor significantly higher microbial richness and alpha diversity. However, describing this difference as 'tenfold higher' (1000% higher) is a substantial overstatement. Comparative studies demonstrate modest increases (e.g., approximately 30–50% higher diversity metrics in isolated groups compared to Western urban controls), far below a 10-fold difference.
Up to 80% of obese individuals who lose weight regain all lost weight within 12 months.
"And this phenomenon, which is medically called recurrent obesity, but is more widely known as yo-yo obesity, characterizes up to 80% of all obese individuals worldwide... but then within 12 months of successfully dieting, 80% of people go on to redevelop obesity or regain all the weight that they've lost, and even regain a little bit more than they originally had." (said at 0:44:59)
The claim overstates the degree and rapidity of weight regain after dieting. The widely cited ~80% figure originates from epidemiological and registry definitions showing that approximately 20% of overweight individuals successfully maintain a weight loss of at least 10% of initial body weight for at least one year (meaning ~80% fail to maintain that specific long-term target). However, failing to maintain a 10% weight reduction is not equivalent to regaining 100% (or more) of lost weight within 12 months; structured weight-loss trials show that individuals typically retain a significant portion of weight loss at 12 months, with full regain occurring more gradually over 3 to 5 years.
Over 100,000 individuals have been tested on thousands of food components and food additives through the Personalized Nutrition pipeline.
"and we've tested thousands of them in in over 100,000 people that underwent our personalized nutrition uh pipeline or project—we found that people distinctly react to foods or food components or food additives, even if they're exposed to the same exact amounts of the same exact component." (said at 0:42:27)
Published peer-reviewed literature from the Personalized Nutrition Project supports the core premise that individuals demonstrate distinct, personalized glycemic and metabolic responses when exposed to identical foods or food additives (PMID: 26590418, PMID: 35987213). However, claiming that over 100,000 individuals were tested across thousands of food components within this research pipeline overstates the cohort sizes published in peer-reviewed studies. The primary study establishing the Personalized Nutrition Project evaluated continuously monitored glycemic responses to 46,898 meals in an 800-person cohort with an independent 100-person validation cohort (PMID: 26590418). Specific clinical trials investigating food additives (such as non-nutritive sweeteners) were conducted in cohorts of 120 participants (PMID: 35987213).
- partial: Personalized Nutrition by Prediction of Glycemic Responses. (Cell 2015) · cited 2901x in the literature
"Here, we continuously monitored week-long glucose levels in an 800-person cohort, measured responses to 46,898 meals, and found high variability in the response to identical meals, suggesting that universal dietary recommendations may have limited utility." (abstract, results, passage verified)
pubmedfull study (doi) - supports: Personalized microbiome-driven effects of non-nutritive sweeteners on human glucose tolera… (Cell 2022) · cited 394x in the literature
"Collectively, human NNS consumption may induce person-specific, microbiome-dependent glycemic alterations, necessitating future assessment of clinical implications." (abstract, conclusions, passage verified)
pubmedfull study (doi)
Antibiotic administration clears the indigenous microbiome, permitting supplemental probiotics to colonize the gut in humans and mice.
"was that both in the human and the mouse setting, when you disrupt the indigenous microbiome by the administration of antibiotics, for example, you kind of empty out the neighborhood. And now you give probiotics, now the neighborhood is empty and the probiotics are no longer met by resistance, and now they can colonize the gut." (said at 1:12:05)
The claim overstates the effect in mice and implies a complete clearance ("emptying out") of the native flora. A study in human volunteers and mouse models (PMID 30193113) demonstrated that while antibiotic disruption enhanced mucosal probiotic colonization in humans compared to baseline homeostasis, it only mildly improved probiotic colonization in mice. Furthermore, antibiotics perturb rather than completely erase the native microbiota, and post-antibiotic probiotic administration markedly delayed the natural reconstitution of the indigenous human gut microbiome.
No probiotic preparation has been approved as a medical drug intervention by the FDA or the European Medicines Agency.
"And and the evidence is that not a single probiotic preparation to date has been approved as a medical intervention by the FDA or by the European counterparts of the FDA." (said at 1:21:21)
The speaker claims that no probiotic preparation has been approved as a medical intervention by the FDA or its European counterparts (such as the EMA). Regulatory bodies like the FDA classify medical live microorganism preparations under the regulatory framework of Live Biotherapeutic Products (LBPs) rather than under the traditional dietary supplement definition of "probiotic." However, the FDA has formally approved live microbial drug interventions to prevent recurrent *Clostridioides difficile* infection, such as Rebyota (fecal microbiota live-jslm) and Vowst (fecal microbiota spores live-brpk). While traditional dietary probiotic products sold over the counter lack FDA/EMA drug approval, the claim that no live bacterial/microbial therapeutic preparation has been approved as a medical drug intervention by the FDA is incorrect.
- contradicts: Advancements in Novel Live Biotherapeutic Products for Clostridioides difficile Infection … (Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2023) · cited 14x in the literature
"Moreover, 2 newer Food and Drug Administration (FDA)-approved live biotherapeutic products (LBP), namely, Fecal Microbiota Live-JSLM and Fecal Microbiota Spores Live-BRPK, have shown promise in preventing CDI recurrence." (abstract, results, passage verified)
pubmedfull study (doi) - contradicts: Update on microbiota-derived therapies for recurrent Clostridioides difficile infections. (Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 2024) · cited 30x in the literature
"Two commercial microbiota-derived medicinal products are approved by the Food and Drug Administration: Rebyota (RBX2660 Ferring Pharmaceuticals, marketed in the United States) and VOWST (SER-109 -Seres Therapeutics, marketed in the United States)..." (abstract, results, passage verified)
pubmedfull study (doi) - contradicts: Live biotherapeutics in the clinic: Regulatory pathways, market dynamics, and future trend… (Progress in molecular biology and translational science 2026) · cited 5x in the literature
"The approvals of Rebyota and Vowst for recurrent Clostridioides difficile infection mark a pivotal milestone, establishing LBPs as a new therapeutic class." (abstract, results, passage verified)
pubmedfull study (doi)
Antibiotic interventions increased human lifespan by close to 30 years within a century.
"You know, they increased, I think, close to 30 years of lifespan within a century, and and at least partially took care of what is considered to be our number one, two, and three cause of mortality for millions of years." (said at 1:28:25)
Total U.S. life expectancy increased by 29.2 years during the 20th century, driven largely by reductions in infectious disease mortality (pneumonia, tuberculosis, and diarrhea/enteritis were indeed the top three causes of death in 1900). However, attributing this full 30-year gain specifically to antibiotic interventions overstates their role. Antibiotics were not introduced into clinical use until the 1940s, whereas substantial declines in infectious mortality occurred earlier in the 20th century as a result of broad public health and environmental interventions, including clean water systems, improved sanitation, food safety, hygiene, and vaccination.
- partial: Control of infectious diseases. (MMWR. Morbidity and mortality weekly report 1999) · cited 49x in the literature
"Deaths from infectious diseases have declined markedly in the United States during the 20th century. This decline contributed to a sharp drop in infant and child mortality and to the 29.2-year increase in life expectancy. In 1900, 30.4% of all deaths occurred among children aged <5 years; in 1997, that percentage was only 1.4%. In 1900, the three leading causes of death were pneumonia, tuberculosis (TB), and diarrhea and enteritis, which (together with diphtheria) caused one third of all deaths." (abstract, passage verified)
pubmed
Unverified means no publication matching the claim was located; it does not prove the claim false. Spotted an error? See the corrections policy - disputes from the people quoted are prioritized.